. This effect is observed at concentrations that do not interfere with the normal functions of these cells. Upon chromatographic fractionation of an aqueous solution of hydrolysed ceftazidime, a high molecular weight fraction (MW 8000) with antiviral activity was isolated. The exact chemical nature of the active component responsible for the anti-HIV activity in vitro appears to be complex and is currently unknown. Inhibition of HIV-1 reverse transcriptase and RNase H activity was observed, however, higher concentrations than those needed to inhibit HIV replication were required. The inhibitory action of the hydrolysed ceftazidime was manifested during the early phase of the HIV-1 life-cycle. Despite a lack of a direct effect of the CD4/gp120 interaction, HIV-1 mediated cell fusion was inhibited by the hydrolysed ceftazidime, suggesting that the active principle acts in a very early stage of the viral life-cycle.
Cephalosporins (as members of the betalactam-antibioticfamily) are among the most widely used antibacterial drugs. In aqueous solutions at room temperature, cephalosporins tend to degrade readily, yielding, among others, highmolecular-weight products (Sugioka et al., 1990) . While studying the relationship between the degradation products and some adverse reactions observed in clinical cases following treatment with these antibiotics, we found that ceftazidime degradation products (CDP) can affect eukaryotic cell proliferation (Do et al. 1987) . From these studies the DNA polymerase α, δ and ε emerged as a potential target. In addition, various DNA polymerases play important roles in the life-cycle of viruses and we have previously shown that cephalosporine derivatives can inhibit replication of the two DNA-containing viruses (herpes simplex I virus and vaccinia virus), but not of two RNA viruses, namely lymphocytic choriomeningitis virus and vesicular stomatitis virus (Cottagnoud et al., 1988) . Here we examine in detail the effect of ceftazidime and its degradation products on HIV-1 relevant enzymes as well as in HIV-1 cellular infection systems. Our data suggest that the hydrolysed ceftazidime acts in a very early stage of the viral life-cycle.
Materials and Methods: Chemistry
Degradation of ceftazidime Ceftazidime (Fortam, GlaxoSmithKline) was dissolved at a concentration of 50 mg/ml in 1 l of water and kept at 70°C for 48 h in a tightly closed glass flask. The hydrolysate (ceftazidime degradation product, CDP) was aliquoted in 200-ml portions and kept at -20°C until further use.
Preparative gel filtration chromatography 10 ml (50 mg/ml, 500 mg) degraded ceftazidime were loaded on to a Sephadex G25 column (dimensions: 2.5×120 cm) equilibrated with bidistilled water and eluted with water at a flow rate of 2.5 ml/min. Fractions (6 ml) were collected and the extinction at 380 nm determined. The fractions were evaporated to dryness in a SpeedVac concentrator, weighed and dissolved in bidistilled water.
Introduction
For analysis and biological testing, fractions from 18 identical chromatography runs were pooled.
Analytical gel filtration chromatography
Analytical gel filtration chromatography was done on a TSKgel GMPW column (TosoHaas, 0.75×60 cm) with 50mM Na-phosphate (pH 7.0), 150 mM NaCl as eluent and a flow rate of 1 ml/min. 20 µl of sample were injected and the extinction at 254 nm of the eluate was monitored. Standards for molecular weight determinations were: ceftazidime (Fortam Glaxo, MW 550), poly-L-aspartic acid (Sigma P-5387, MW 14′400), poly-L-aspartic acid (Sigma P-6762, MW 28′800). Molecular weight determinations were done by plotting the retention times of standards versus the log of molecular weights.
Materials and Methods: Virology

Cell lines
The following cells were obtained through the AIDS Research and Reference Reagent Program, Division of AIDS, NIAID, NIH: MT-2 cells, transformed with and continuous producer of HTLV-I virions from D Richman (Harada et al., 1985; Haertle et al., 1988) ; CEM-SS cells from P Nara (Nara et al., 1987; Nara et al., 1988) ; the permanently infected cell lines H9/HTLV-IIIB NIH 1983 (H9/HIV-1/IIIB cells) from R Gallo Ratner et al., 1985) ; Molt-4 Clone 8 from R Desrosiers (Kikukawa et al., 1986; Daniel et al., 1988) , U937 cell line was obtained from the American Type Culture Collection (Sundstrom and Nilsson, 1976) . These cell lines were maintained in complete medium containing RPMI 1640 supplemented with 10% fetal calf serum, 10 mM HEPES, 2 mM L-glutamine (all purchased from Gibco, Paisley, Scotland) and 100 U/ml penicillin, 100 µg/ml streptomycin (Amimed, Basel, CH).
HIV-1
The virus strains HIV-1/LAV.04, HIV-1 NL4-3 (Adachi et al., 1986) and HIV-1/Z-84 were gifts from M Martin (Barre-Sinoussi et al., 1983; Yourno et al., 1988) . Selective monocytotropic isolate HIV-1/Ada-M was a gift from H Gendelman (Gendelman et al., 1988) .
Enzymes and other reagents
HIV-1 RT heterodimer p66/p51 was overexpressed in E. coli (gift of L Loeb, University of Washington) and purified based on a previous published procedure . The three cellular DNA polymerases α, δ and ε were isolated as described (Weiser et al., 1991) . gp120 from HIV-1SF2 was obtained trough the AIDS Research and Reference Reagent Program, Division of AIDS, NIAID, HIH, from N Haigwood of Chiron Corporation (Levy et al., 1984; Sanchez-Pescador et al., 1985; Haigwood et al., 1990) . Recombinant gp120(HIV-1)-FITC was purchased from ABT American Bio-Technologies, Cambridge Mass., USA. Purified and PE conjugated Leu 3a monoclonal antibody and mouse IgG1-PE were purchased from Becton Dickinson Immunocytometry Systems, San Jose, Calif., USA. Purified human IgG, human AB serum, and bovine serum albumin were purchased from Sigma Chemical Company, St Louis, Mo., USA. Purified human Fc fragment was purchased from Chemicon International, Temecula, Calif., USA. Ribo-and deoxyribonucleosides triphosphates and poly-and oligonucleotides were from Amersham (radioactively labelled with [ 3 H]) or from Pharmacia (unlabelled). AZT (3′-azido-3′-deoxythymidine) was purchsed from Sigma Chemical Company. Propidium iodide was purchased from Molecular Probes, Eugene, Oreg., USA. Ceftazidime: Fortam was from Glaxo, Greenford, UK. HIV-1 protease inhibitor CGP 53437 was synthesised at NOVARTIS.
HIV-1 infection of MT-2 cells
MT-2 cells were seeded in 96-well U-bottom tissue culture plates at 2×10 4 cells in 50 µl per well, in complete medium in the presence or absence of 50 µl test substances and 100µl virus (MOI, 0.14 TCID 50 /cell). After 4 days of incubation at 37°C, 5% CO 2 , 10 µl-samples of the culture supernatants were collected and stored at -20°C. Virus production was determined as virus associated RT activity in these samples (see below). Viability of the infected or non infected cells was measured on day 4 using the XTT (2.3bis(2-methoxy-4-nitro-5-sulfophenyl)-5[(phenylamino) carbonyl]-2H-tetrazoliumhydroxyde) method (Scudiero et al., 1988) . This reagent is metabolized by viable cells to a soluble coloured product. Five hours after addition of XTT and incubation at 37°C, the concentration of the coloured product was determined by measuring the absorbance at 450 nm (OD 450 ). Cytopathic effect (CPE) was calculated and expressed as: % CPE = 100% -OD 450 (infected cells) × 100%/OD 450 (non infected cells). The CPE ED 50 is the 50% inhibitory concentration for the cytopathicity of HIV-1 in MT-2 cells.
Isolation, culture and HIV infection of peripheral blood lymphocytes
Peripheral blood mononuclear cells (lymphocytes and monocytes) were obtained from the blood of healthy HIV seronegative donors by a combination of leukapheresis and counter-current centrifugal elutriation, as previously described (Lazdins et al.. 1990; Lazdins et al., 1991) . Lymphocytes were cultured in the presence of 0.25 µg/ml phytohaemagglutinin (Welcome diagnostics, Temple Hill, Dartford, UK) for 2 days in RPMI-1640 (Gibco, Paisley, UK), 50 U/ml penicillin, 50 µg/ml streptomycin (Amimed, Basel, Switzerland), 2 mM L-glutamine and 10 mM HEPES buffer (Gibco). Activation was confirmed by the increase in cell size (light scattergram, FCM analysis). These cells were resuspended in complete medium containing 10% FCS (Gibco) and infected with HIV-1 for 6 h. Following viral adsorption, cells were washed and resuspended in complete medium supplemented with 100 U/ml of human recombinant IL-2 (Genzyme, Cambridge, Mass., USA). 9×10 4 cells/well (0.3 ml) were plated in flat bottom 96-well plates (Nunc A/S, Roskilde, Denmark). Two-thirds of the culture medium was replaced every 3days.
Isolation, culture and HIV infection of peripheral blood monocytes
Monocytes isolated by the above described procedure were cultured in Dulbecco's Minimum Essential Medium with high glucose (Gibco) supplemented with 10% human AB type serum (Sigma), 50 U/ml penicillin, 50 µg/ml streptomycin (Amimed), 2 mM L-glutamine and 1 mM sodium pyruvate (Gibco). The cultures (15×10 6 cells/10 ml) were maintained in bacteriological Petri dishes (Sterilin, Feltman, Middlesex, UK). After 1 week, the cultures were supplemented with 10 ml of fresh medium. After 14 days in culture the monocytes had acquired the macrophage phenotype. The cells were detached after incubating the monolayers in PBS w/o calcium or magnesium for 2 h at 5°C. The cells were washed and resuspended in the above described medium and re-plated in 96 flat bottom well plates at 4-5×10 4 cells per well in 0.3 ml of medium. Once the monolayer was established the cells were infected with 50 µl of cell culture medium containing the viral inoculum (2000 cpm/µl RT activity). Following a 4 h adsorption period at 37°C, the virus-containing supernatants were removed and 0.3 ml of fresh medium added. Cell supernatants were changed every 4-5 days after infection. The experiments were terminated on day 21 after infection.
Co-culture infection of the lymphoid cell line CEM-SS by permanently infected H9/HTLV-IIIB NIH 1983 cell line (H9IIIB)
A modification of a previously described assay was used (Nara et al., 1987) . The H9IIIB and CEM-SS cells in log phase growth were washed twice, resuspended in prewarmed fresh tissue culture medium, 75 µl (5×10 4 ) of each cell type was seeded into 96-well flat-bottom tissue culture plates. Immediately after, 50 µl of medium with or without test substances was added. After 20 h of incubation at 37°C, 5% CO 2 , 10 µl of cell free supernatant were removed and stored at -20°C until RT activity was determined. Formation of syncytia was monitored using an inverted microscope.
Binding of Leu-3a to MT-2, U937 cell lines and in vitro differentiated macrophages
Cell labelling was performed in 96 V bottom well plates (Nunc). To block non-specific binding, 0.5×10 6 cells were resuspended in 40 µl of blocking buffer (10% human serum, 500 µg/ml human IgG, 200 µg/ml human IgG FC, 0.9% BSA-PBS + 0.1% Na azide) for 20 min at 4°C. At this point 10 µl of PBS or PBS containing different CDP concentrations (15-120 µg/ml) were added to the wells. The cells were incubated for 30 min at 4°C. At this time control antibody IgG 1 -PE (50 µg/ml) or Leu-3a-PE (10µg/ml) were added and incubated at 4°C for 30 min. The cells were washed twice in PBS and resuspended in PBS containing propidium iodide (PI) at 5 µg/ml and live cells (PI negative) were analysed by FCM.
gp120 cell binding assay
For this measurement two assays were used: (a) direct evaluation of gp120 binding to CD4 positive cells: 2.5×10 4 Molt-4clone 8 cells were resuspended in 20 µl of blocking buffer (see above) containing 40µg/ml gp120 FITC either in the presence or absence of CDP (180-6 µg/ml) or unlabelled Leu-3a (4-0.2µg/ml). After incubation for 1h at 4°C the cells were washed and resuspended in PBS. Living cells (10000 events) were analysed by flow cytometry (FCM) using a HFCScan flowcytometer and FCScan Research Software (Becton Dickinson). Autofluorescence was determined by analysing cells that were not exposed to gp120-FITC. (b) Indirect evaluation of gp120 binding: MT-2 cells (0.5×10 6 /25µl/well) were resuspended in blocking buffer and incubated at 4°C for 45min. Cells were treated with or without soluble gp120 (100µg/ml) for 5min in the presence or absence of CDP (100µg/ml). This was followed by immediate addition of Leu-3a PE and incubation continued for 1h at 4°C. The cells were washed three times in PBS, resuspended in PBS containing 2% (v/v) formaldehyde and stored at 4°C in the dark until further analysis. 10000 events were collected and analysed by FCM using the FCScan and FCScan Research Software.
Virus detection: cell free supernatant RT activity
Virus production was evaluated by determining RT activity in cell free supernatants by a previously published method (Alteri et al., 1993) . The following modifications (personal communication R Repaske, NIH, USA) have been introduced: the reaction mixture was adjusted to 0.1% Nonidet P-40, 0.8 mM EDTA, and 10 µg of poly rA• oligo (dT) per ml as the template primer was used. The assay was performed in a 96-well plate format.
Enzymatic assays
Retroviral RT and RNase H assays were performed as described earlier . Each IC 50 value derives from curves where five or more different concentrations were measured in double determinations. The enzymes were titrated before each experiment so that inhibition could always be measured at near saturation of the reaction.
The three cellular DNA polymerases α, δ and ε activities were assayed as previously described (Weiser et al., 1991) .
Results
Effect of hydrolytically degraded ceftazidime (CDP) on acute infection of MT-2 cells with different HIV-1 strains MT-2 cells were exposed to CDP during infection and replication of HIV-1 as described in Materials and Methods. HIV-1 replication was assessed either by determining the amount of RT activity produced by infected cells as well as by quantifying the HIV-1 induced cytopathic effect. In addition, the effect of CDP on cell viability of non infected MT-2 cells was also studied. Figure 1 shows the results of such an experiment. In 10 different experiments, total inhibition of HIV-1 induced cytophatic effect and 90% reduction of RT activity was achieved at concentrations ranging between 10 and 100µg/ml (10 experiments). Toxicity on non infected cells was only evident, when CDP concentrations higher than 500 µg/ml were used. The effect of CDP in inhibiting HIV-1 acute infection of MT-2 cells was also confirmed using two additional divergent HIV-1 strains. The Z-84 and pNL-4 strains of HIV-1 showed similar sensitivity (the ED 90% for supernatant RT reduction was 3 µg/ml) to CDP as that described for HIV-1/LAV (data not shown).
Effect of CDP on the replication of HIV-1 in primary human cells
To exclude an indirect effect of CDP on the phenotype of MT-2 cells (transformed by and continuously producing HTLV-I) that could cause inhibition of HIV replication, we next examined the effect of CDP on HIV-1 infection in primary human lymphocytes and in vitro differentiated blood monocytes (macrophages). These cells were infected as described in Materials and Methods. CDP was added following infection and with each medium change. HIV-1 production was monitored by determining RT activity in cell free supernatants before each medium change. Figure 2a shows the effect of CDP on the RT production in lymphocytes infected with HIV-1/LAV. A dose-dependent shift on the time and magnitude of the peak of RT production was observed. CDP at 100 µg/ml totally suppressed RT production. Figure 2b shows the effect of CDP on RT production by macrophages infected with the monocytotropic HIV-1/Ada-M. Total virus suppression was seen at concentrations of 125 µg/ml or higher; however, a significant reduction was achieved even with 15 µg/ml. When the effect of CDP on IL-2 dependent (non-HIV infected) human lymphocyte proliferation was examined, no changes could be detected (highest concentration tested = 600 µg/ml). Similarly, the number of macrophages (non-HIV infected) recovered after 3 weeks of culture was not affected by CDP (highest concentration tested 1200 µg/ml, data not shown). Interestingly, CDP (up to 1200 µg/ml) had no effect on supernatant RT production (data not shown) when added to macrophage cultures at a time at which the HIV infection had spread to most of the cells, and virus production had reached steady state level at day 14 post-infection.
Time-course of addition of CDP on HIV-1 replication in MT-2 cells
To gain insight on the mechanism of action of CDP induced inhibition of HIV replication, CDP (18 µg/ml) was added at different times after HIV-1 infection ( Figure  3 ). When the compound was added together with the virus during the infection period or 30 min after infection, maximal inhibition of HIV replication was observed. However, if CDP was added 1 h after infection, a loss of anti-HIV activity was evident. This loss of activity was time dependent, when CDP was added 5 h after infection inhibition on HIV-1 replication could no longer be detected. For comparison, when AZT (15 µM) was used, the drug was still 
Effect of CDP on gp120/CD4 interaction
Since the experiments described so far have suggested an effect of CDP on the 'early' phase of the HIV-1 life-cycle, we designed experiments to evaluate the effect of CDP on cellular CD4 expression as well as on the CD4/gp120 interaction. The expression of CD4 molecules can be readily assessed on MT-2, U937 cell lines or on macrophages by evaluating the specific binding of the monoclonal antibody Leu-3a to these cells. This antibody recognises the site on the CD4 molecule that is essential for interaction with HIV-1 gp120. When cells were exposed to Leu-3a directly coupled to the fluorochrome phycoerythrin (PE) in the presence of CDP (120 µg/ml), the amount of antibody positive cells (FCM) analysis was indistinguishable from that of cells that were exposed to Leu-3a PE in the absence of CDP (data not shown). These results indicated that CD4, and specifically the HIV binding site on this molecule, is not affected by CDP. To further explore the role of this target we examined the effect of CDP on gp120 binding to the HIV-1 susceptible MOLT-4 cells. These cells were exposed to soluble fluoresceinated (FITC) HIV-1 gp120 as described in the Materials and Methods section and specific cell binding was evaluated by FCM analysis. CD4-dependent binding of gp120 to MOLT-4 cells could be clearly demonstrated, and this interaction was fully prevented by the addition of 1 µg/ml of Leu-3a monoclonal antibody. On the other hand, CDP up to 300 µg/ml did not inhibit gp120 binding to MOLT-4 cells (data not shown). These results indicate that HIV-1 gp120 interaction with CD4 is not affected by CDP.
Effect of CDP on cell-to-cell infection
Another potential mechanism of action of CDP could be the fusion of HIV virus membrane with cell membrane after binding CD4 + cells. It is believed that this is the mechanism responsible for the formation of giant cells seen during in vitro HIV infection. To study this mechanism, we used a previously described method (Nara et al., 1987 (Nara et al., , 1988 , which employs chronically HIV-1 producing H9/IIIB infected cells that are co-cultured with CEM-SS cells leading to syncytia formation. Results are shown in Figure 4 . H9/IIIB cells produced low levels of HIV RT activity (300 cpm/µl/20 h). When cultured with CEM cells (ratio 1:1) the RT activity increased to 5400 cpm/µl/20 h. This increase in virus production was paralleled with exten-sive syncytia formation. Both RT production and syncytia formation could be inhibited to background levels by an antibody directed against CD4 (Leu-3a). When CDP was examined in this system, CDP concentrations of 150 µg/ml were required to achieve effects similar to those described with Leu-3. CPD had no effect on the constitutive virus production of chronically infected macrophages or H9/IIIB cells (data not shown).
Effect of CDP on retroviral and host enzymes
Since in some cellular systems the antiviral effects were seen with concentrations of CDP lower than those required to achieve fusion inhibition, we examined other virus specific 'early' targets such as HIV-1 RT and RNase H (Table  1 ). In vitro inhibition of viral enzymes was achieved at concentrations lower than those required to inhibit virus replication. On the other hand, when the three cellular DNA polymerases α, δ and ε were tested, a remarkable sensitivity to CDP was found. All three DNA polymerases were inhibited at concentrations 5-10 times lower than those found for HIV-RT, and similar to those required to inhibit HIV-1 replication in cells. However, despite these findings, no in vitro cytotoxicity of CDP with concentrations up to 500 µg/ml was observed, suggesting that the in vitro effect on these enzymes does not translate into an antiproliferative effect that could explain the reduction of virus replication.
Determination of the molecular weight of the active CDP principle
The crude hydrolysate of ceftazidime was chromatographed on a Sephadex G25 column as described in the Materials and Methods. Three 6-ml fractions were pooled, evaporated to dryness, resuspended in water at 10mg/ml and tested in appropriate concentrations for their inhibition of the HIV-induced cytopathic effect. Anti-HIV activity was identified mainly in fractions that eluted in the high molecular weight region ( Figure 5) . A fraction eluted at low molecular weight was also identified to be anti-HIV active. The material from 18 consecutive chromatographic runs on Sephadex G25 were pooled. Pools 1, 2 and 3 were assembled from the high molecular weight region and pool 4 from the low molecular weight part. The four pools were tested for anti-HIV activity (inhibition of cytopathic activity and inhibition of production of supernatant RT activity), HIV enzyme (RT and RNase H) inhibition and cytotoxic effect. These results are summarized and compared to CDP in Table 2 . The highest anti-HIV activity was found in pool 1 (which eluted the highest molecular weight material). Pools containing lower molecular weight materials (2, 3, 4) had significantly reduced anti-HIV activity. It is interesting, however, to indicate that the material that constituted pool 4 had a clearly anti-HIV activity, while the material from immediately preceding fractions was completely inactive. On the other hand, the inhibitory effect on HIV RT and RNase H enzymatic activities was similarly distributed as the anti-HIV activity, however, approximately 10-fold higher concentrations were required. No cellular toxicity was observed with this material even at concentrations significantly higher than those required to inhibit HIV replication or enzymatic activity. To determine the molecular weights of these pools 1, 2 and 4 were subjected to analyt- The chromatography was carried out as described in Materials and Methods. Three consecutive 6-ml fractions were pooled, evaporated to dryness, weighed and tested for antiviral activity (cytopathic effect, CPE ED 50 ). Squares: amount of CDP (mg); bars: antiviral activity determined with HIV-1 infected MT-2 cells as described in Materials and Methods. The four pools, 1-4, indicated, are further analysed in Figure 6 . ical gel-filtration chromatography on a TSK-gel GMPW column ( Figure 6 ). The material in pools 1, 2 and 3 showed a homogenous peak that eluted at a retention volume (19.4 ml) corresponding to a molecular weight of 8000. In contrast, pool 4 was found not to be homogeneous, showing several peaks with a higher retention volume (20-23 ml) than that observed for pools 1, 2 and 3. The molecular weights were estimated to be in the range of MW 600-5000.
Discussion
We previously described a product (HP 0.35) isolated from CDP that was a potent inhibitor of HIV-1 RNase H . However, when examined in HIV replication the material was shown to be inactive (data not shown). Purified HP 0.35 turned out to be labile and it tends to polymerize. It was proposed that low levels of polymerized material in the purified HP 0.35 have resulted in the reported activity (Baertschi et al., 1997) . In contrast, the crude CDP effectively inhibited HIV-1 replication in acute cellular systems using cell lines, primary lymphocytes or macrophages infected with different HIV-1 isolates. This prompted us to examine the anti-HIV activity of this material in more detail, as well as to characterize and isolate the active component present in the CDP mixture. Our work led us to the findings that we are dealing with a polymer of MW 8000. The work to characterize the polymer is underway and the mild degradation conditions suggest that it is a homopolymer (Hobi R, unpublished results) . Surprisingly, the antiviral effect was not observed when chronically infected cells were examined, indicating that the target for this substance is most likely to be among the early phase of the viral life-cycle. This was further confirmed by excluding activity against HIV-1 protease or on the function of TAT or rev (data not shown). While the isolated product inhibit HIV-1 RT and its RNase H enzymatic activity, the concentrations required to achieve maximal inhibition were considerably higher than those required to inhibit HIV replication. Interestingly, this material had an effect on inhibiting host DNA polymerases in a concentration range similar to that required to inhibit HIV replication (data not shown). However, since no effect on cell proliferation was observed even at 100-fold higher concentrations we conclude that it is most likely that this material did not penetrate the cells and that the anti-HIV activity is due to a cell surface mechanism that interferes with a critical step in the lifecycle of HIV. We excluded the interaction of CD4 and gp120 as this site (as it has been claimed for dextran sulphate). On the other hand, a clear effect on the fusion of HIV-1 infected and non-infected cells was observed. This, together with the experiments in which different times after the addition of the active principle were tested, points to a possible role in the process of virus fusion with the host cell membrane. Two additional experimental strategies might give more insight into the mode of action of CDPs: the follow-up blocking of cDNA intermediates of HIV replication in the presence of CDPs by PCR (Sonza S et al., 1996) , and secondly, directly testing the inhibition of gp120/CD4 interaction by an enzymelinked immunoabsorbent assay (Gilbert M et al., 1993) . Moreover, an attractive target to further examine CDP would be the HIV-1 co-receptor CCR-5 (Trkola et al., 1996; Wu et al., 1996) . Such surface effect is further supported by the fact that the isolated CDP is a highly negatively charged molecule. However this alone can not explain the anti-HIV activity, since CDP was not able to affect other cellular events such as the IL-2 induced T cell proliferation that requires surface receptor activity. Such events should be inhibited by highly negatively charged molecules (data not shown). Work to further characterize and define the structure and function of the minimal active moiety is currently underway.
In conclusion, our results indicate that the antibiotic ceftazidime represents a suitable source for the isolation of a novel and potent agent, which is able to interfere with HIV-1 replication in in vitro cellular systems without interfering with the normal replication, function and phenotype of lymphocytes or macrophages. R Hobi et al. Pools 1-4, from preparative gel filtration, were tested analytically on a TSK GMPW column. Pools 1, 2 and 3 showed essentially a homogeneous peak at a retention time corresponding to a molecular weight of 8000, while pool 4 contained several products with lower molecular weights.
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